Longer Reproductive Lifespan Cuts Cerebral Small Vessel Disease Risk
A Swedish study of older women finds longer lifetime estrogen exposure from reproductive years and hormone therapy is linked to reduced cerebral small vessel disease and healthier brain white matter.
Longer reproductive lifespan and the use of hormone therapy are linked to a significantly lower risk of cerebral small vessel disease and improved brain white matter integrity in older women. A new study of 352 women aged 70 found each additional year of reproductive life was associated with an 8% reduction in the odds of having multiple signs of this vascular brain condition.
Menopausal hormone therapy was associated with a 59% lower risk of a greater small vessel disease burden. It was also linked to increased integrity of the brain's white matter microstructure. The most favorable vascular brain health was seen in women who used oral contraceptives earlier in life and menopausal hormone therapy later.
Population and Methodology
The research examined 352 cognitively unimpaired women from the 1944 Gothenburg H70 birth cohort. All participants had brain MRI scans at age 70, with 286 also undergoing scans at age 75. The study assessed four specific signs of cerebral small vessel disease on those scans.
The average reproductive lifespan among participants was 37.1 years. At baseline, the mean Mini-Mental State Examination score was 29.2, indicating normal cognitive function. About one-third of the women were carriers of the APOE4 genetic variant linked to Alzheimer's risk.
Hormone Therapy and Risk Reduction
The data showed a clear gradient of benefit linked to hormone exposure. Women using menopausal hormone therapy had 59% lower odds of a higher small vessel disease burden after adjusting for factors like education and cardiovascular health. Hormonal therapy use was consistently associated with greater integrity of brain white matter.
The most pronounced benefits were observed in women with combined lifetime exposure. Those who used oral contraceptives earlier and menopausal hormone therapy later had the lowest small vessel disease burden and the greatest white matter integrity. Among APOE4 carriers, menopausal hormone therapy was additionally associated with greater cortical thickness in brain regions typically affected by Alzheimer's disease.
Limitations and Context
The findings rely on self-reported histories of hormone use, which may be subject to recall bias. The study also lacked detailed information on the specific types, doses, and durations of oral contraceptives and hormone therapy used. All participants were cisgender women, limiting generalizability.
Researchers emphasize the study shows an association, not causation. Clinical trials are needed to prove direct effects. The potential mechanism may involve estrogen's known protective effects on neuronal cells and brain blood vessels. The work was supported by multiple Swedish research and dementia foundations.
The potential for reproductive history and hormone therapy to inform personalized brain health strategies represents a concrete step toward understanding women's unique cognitive aging pathways.
